We are live on ! Find out more
IHAM

Integral Health Asset Management Portfolio holdings

AUM $2.09B
1-Year Est. Return 112.84%
This Fund
S&P 500
This Quarter Est. Return
-9.51%
1 Year Est. Return
+112.84%
3 Year Est. Return
+485.32%
5 Year Est. Return
+783.01%
10 Year Est. Return
–
AUM
$486M
AUM Growth
+$102M
Cap. Flow
+$150M
Cap. Flow %
30.89%
Top 10 Hldgs %
40.72%
Holding
86
New
15
Increased
40
Reduced
9
Closed
21

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$21.9M
2
SNY icon
Sanofi
SNY
+$18.6M
3
CNC icon
Centene
CNC
+$16.6M
4
DXCM icon
DexCom
DXCM
+$15.2M
5
GH icon
Guardant Health
GH
+$14.1M

Top Sells

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$15.5M
2
GMED icon
Globus Medical
GMED
+$13.3M
3
ACHC icon
Acadia Healthcare
ACHC
+$9.83M
4
AMED
Amedisys
AMED
+$6.89M
5
CI icon
Cigna
CI
+$5.99M

Sector Composition

Rank Sector Weight
1 Healthcare 97.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ELV icon
1
Elevance Health
ELV
$81.5B
$32.7M 6.73%
67,840
+22,840
+51% +$11.3M
CNC icon
2
Centene
CNC
$30.7B
$29.6M 6.09%
350,000
+200,000
+133% +$16.6M
LLY icon
3
Eli Lilly
LLY
$1.02T
$23.7M 4.87%
+73,059
New +$21.9M
CYTK icon
4
Cytokinetics
CYTK
$10.5B
$20.6M 4.24%
525,000
+55,000
+12% +$2.21M
SNY icon
5
Sanofi
SNY
$103B
$17.5M 3.6%
+350,000
New +$18.6M
GH icon
6
Guardant Health
GH
$21.7B
$15.5M 3.2%
385,291
+285,291
+285% +$14.1M
AZN icon
7
AstraZeneca
AZN
$263B
$15.5M 3.19%
117,415
+67,415
+135% +$8.85M
NVST icon
8
Envista
NVST
$4.44B
$14.9M 3.06%
386,165
+136,165
+54% +$5.72M
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
$14.2M 2.93%
574,029
+174,029
+44% +$3.84M
MCK icon
10
McKesson
MCK
$100B
$13.6M 2.8%
+41,748
New +$13.4M
SAGE
11
DELISTED
Sage Therapeutics
SAGE
$13.3M 2.74%
412,257
+101,257
+33% +$3.39M
THC icon
12
Tenet Healthcare
THC
$20.5B
$13.2M 2.71%
250,485
+120,485
+93% +$8.38M
CVS icon
13
CVS Health
CVS
$133B
$13.1M 2.69%
140,898
+50,898
+57% +$4.97M
DXCM icon
14
DexCom
DXCM
$31.5B
$12.4M 2.56%
+166,991
New +$15.2M
BMRN icon
15
BioMarin Pharmaceuticals
BMRN
$11.6B
$10.5M 2.15%
126,286
+46,286
+58% +$3.69M
RVTY icon
16
Revvity
RVTY
$12.6B
$9.65M 1.98%
67,840
-7,160
-10% -$1.07M
ZNTL icon
17
Zentalis Pharmaceuticals
ZNTL
$337M
$9.56M 1.97%
340,243
+125,243
+58% +$3.32M
MRK icon
18
Merck
MRK
$322B
$9.52M 1.96%
104,369
+29,369
+39% +$2.6M
SWAV
19
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$8.98M 1.85%
46,966
+16,966
+57% +$2.99M
KURA icon
20
Kura Oncology
KURA
$800M
$8.46M 1.74%
461,310
+124,310
+37% +$1.79M
ALKS icon
21
Alkermes
ALKS
$8.22B
$7.8M 1.61%
261,966
+11,966
+5% +$344K
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$7.57M 1.56%
704,490
+480,490
+215% +$3.96M
PRGO icon
23
Perrigo
PRGO
$1.4B
$7.41M 1.52%
+182,645
New +$6.78M
RLAY icon
24
Relay Therapeutics
RLAY
$4.1B
$7.31M 1.5%
436,262
+109,262
+33% +$2.34M
ALNY icon
25
Alnylam Pharmaceuticals
ALNY
$27.5B
$6.85M 1.41%
+46,966
New +$6.66M
1
2 3 4

Similar funds

CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
ACM
Analog Century Management New York $2.09B AUM 186.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.09B AUM 33.67% 1-Year Est. Return
ACG
Aventail Capital Group New York $2.09B AUM 43.81% 1-Year Est. Return
NSUP
NLB Skladi upravljanje premozenja Ljubljana $2.09B AUM
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
ACP
Avantyr Capital Partners New York $2.08B AUM
TA
TruWealth Advisors Metairie, Louisiana $2.08B AUM 21.15% 1-Year Est. Return

Integral Health Asset Management's Q2 2022 Portfolio in Review

As of Q2 2022, Integral Health Asset Management held 86 positions worth $486M, up 27% from $384M the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Integral Health Asset Management deployed $150M of net new capital in Q2 2022, opening 15 new positions and adding to 40 existing holdings. Its largest new stake was Eli Lilly: 73,059 shares worth $23.7M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Seagen Inc. Common Stock, an estimated $2.69M trimmed.

  • Integral Health Asset Management's largest Q2 2022 buy was Eli Lilly: 73,059 shares worth $23.7M.
  • Integral Health Asset Management added most to Centene in Q2 2022, an estimated $16.6M increase.
  • Integral Health Asset Management's biggest Q2 2022 reduction was Seagen Inc. Common Stock, cutting an estimated $2.69M.
  • Integral Health Asset Management fully exited Pfizer in Q2 2022, selling an estimated $15.5M.
  • Integral Health Asset Management's ten largest holdings make up 41% of its $486M portfolio in Q2 2022.
  • Integral Health Asset Management opened 15 new positions and closed 21 in Q2 2022.
  • Integral Health Asset Management's portfolio value rose 27% quarter-over-quarter to $486M.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.